SEQIRUS
LIVE

Serial Number

86727032

Owner

Seqirus UK Limited

Attorney

Nancy Sabarra

Filing Date

Aug 17, 2015

Add to watchlist:

No watchlists yet
View on USPTO

SEQIRUS Trademark

Serial Number: 86727032 • Registration: 5184313

SEQIRUS is a trademark filed by Seqirus UK Limited on August 17, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Seqirus UK Limited (138 trademarks)

Point, 29 Market Street

Entity Type: 98

Trademark Details

Filing Date

August 17, 2015

Registration Date

April 18, 2017

Published for Opposition

December 13, 2016

Goods & Services

[ Medical services; ] medical information services; [ health care services; health care information services, namely, internet-based health care information services; providing medical information concerning blood products; ] providing medical information concerning vaccines [, anti-venoms and immunohematology products, namely, diagnostic reagents; patient support services, namely, providing an Internet-based database of patient medical information, where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community ]

[ Chemical and biological reagents for scientific and non-medical purposes; cell cultures and media for laboratory, scientific and research use; test kits for scientific and non-medical laboratory use for anti-body screening, blood grouping or detection of specific blood cells, antigens and immunoglobulin subtypes; chemical preparations for scientific and industrial purposes; diagnostic and testing agents for scientific and non-medical purposes; Chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells ]

Pharmaceutical preparations and substances for the [ treatment and ] prevention of [ blood disorders, bleeding disorders, and ] diseases caused by [ bacteria and ] viruses; vaccines; [ blood products, namely, immunoglobulins for medical or clinical use; medicated serums for the treatment of influenza; anti-virals; ] influenza vaccines; adjuvants and antigens for medical purposes; [ blood products, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic use; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; test kits, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, Rheysys Factor D Antigen reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies and Immunoglobulin subtypes; ] pharmaceutical preparations, namely, therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases [ ; pharmaceutical preparations, namely, reagents for medical and clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes ]

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Apr 18, 2026 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 16, 2024 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 16, 2024 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 16, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Oct 18, 2023 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 18, 2022 REM1
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 25, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 25, 2019 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 18, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 18, 2018 REAP
REGISTERED-PRINCIPAL REGISTER
Apr 18, 2017 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Mar 13, 2017 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 13, 2017 AITU
NOTICE OF ALLOWANCE CANCELLED
Mar 6, 2017 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Mar 6, 2017 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 7, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 13, 2016 NPUB
PUBLISHED FOR OPPOSITION
Dec 13, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 23, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 10, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 3, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 31, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 31, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 24, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 20, 2016 GNRN
NON-FINAL ACTION E-MAILED
Sep 20, 2016 GNRT
NON-FINAL ACTION WRITTEN
Sep 20, 2016 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 1, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 1, 2016 CRFA
ASSIGNED TO LIE
Aug 25, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 18, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 1, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 1, 2016 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 24, 2016 GNRN
NON-FINAL ACTION E-MAILED
Jun 24, 2016 GNRT
NON-FINAL ACTION WRITTEN
Jun 24, 2016 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 2, 2016 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 2, 2016 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 3, 2015 GNRN
NON-FINAL ACTION E-MAILED
Dec 3, 2015 GNRT
NON-FINAL ACTION WRITTEN
Dec 3, 2015 CNRT
ASSIGNED TO EXAMINER
Dec 1, 2015 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 21, 2015 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 20, 2015 NWOS
NEW APPLICATION ENTERED
Aug 20, 2015 NWAP